Experts say Medicaid rebate change is behind inhaler price cuts

Three of the four major inhaler manufacturers have announced plans to cap patient copays for all their inhalers at $35 a month in recent weeks, in addition to lowering the list prices of some of those products.

Related Keywords

Oregon ,United States ,Capitol Hill ,American ,Ron Wyden ,Flovent Diskus ,Spiriva Respimat ,Anna Kaltenboeck ,Spiriva Handihaler ,Bernie Sanders ,Advair Diskus ,Drug Administration ,Senate Health ,Harvard Medical School ,Amneal Pharmaceuticals Inc ,Teva Pharmaceutical Industries Ltd ,Boehringer Ingelheim ,Senate Finance Committee ,Call Inc ,Astrazeneca ,Tribune Content Agency ,Glaxosmithkline ,Lauren Clason ,Oregon Democrat Ron Wyden ,Prescription Drug Reimbursement ,Will Feldman ,Harvard Medical ,Pensions Chairman Bernie Sanders ,Federal Trade Commission ,Orange Book ,Amneal Pharmaceuticals ,Roll Call ,All Rights ,